Compare CLBT & BLLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CLBT | BLLN |
|---|---|---|
| Founded | 1999 | 2016 |
| Country | Israel | United States |
| Employees | 1285 | 713 |
| Industry | Computer Software: Prepackaged Software | Medical Specialities |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.4B | 3.9B |
| IPO Year | N/A | N/A |
| Metric | CLBT | BLLN |
|---|---|---|
| Price | $13.14 | $86.22 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 7 |
| Target Price | $22.50 | ★ $126.71 |
| AVG Volume (30 Days) | ★ 2.2M | 620.6K |
| Earning Date | 05-14-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $21.45 | $46.29 |
| Revenue Next Year | $17.47 | $30.14 |
| P/E Ratio | $45.29 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $11.03 | $61.96 |
| 52 Week High | $19.98 | $138.70 |
| Indicator | CLBT | BLLN |
|---|---|---|
| Relative Strength Index (RSI) | 49.07 | 51.80 |
| Support Level | $12.67 | $81.06 |
| Resistance Level | $13.89 | $97.36 |
| Average True Range (ATR) | 0.69 | 8.62 |
| MACD | 0.03 | -0.51 |
| Stochastic Oscillator | 63.07 | 41.41 |
Cellebrite DI Ltd provides AI-powered digital investigative and intelligence solutions that help public and private sector customers transform investigative workflows, make digital data more accessible and actionable, and improve the efficiency of mobile research and application security. Its solutions support law enforcement, defense, and intelligence agencies in advancing investigations, border security, counterterrorism, intelligence operations, and cyber operations. The company's software also enables enterprises and service providers to collect and review data for corporate investigations, eDiscovery, incident response, and mobile application validation. It operates in the Americas, APAC, and EMEA, with the majority of revenue from the Americas.
BillionToOne Inc is a molecular diagnostics company. It offers a portfolio of ultrasensitive tests covering prenatal genetic testing, cancer therapy selection, and response monitoring, which are based on its Quantitative Counting Templates (QCT) molecular counting platform. The company's product portfolio comprises UNITY, a portfolio of prenatal testing products that can conduct fetal risk analysis without requiring a paternal sample; Northstar Select, a ultrasensitive liquid biopsy test that provides insights into appropriate therapies for stage III or IV cancer patients; and Northstar Response, a tissue-free, pan-cancer, liquid biopsy test that measures several genomic loci uniquely methylated in cancer to provide insight into dynamic changes in therapy response.